ERITROPOYETINA HUMANA MODIFICADA

Una eritropoyetina humana modificada con un tiempo de vida media en plasma aumentado, con actividad eritropoyetica menor al 0,5 % en relacion a una eritropoyetina nativa, que mantiene su capacidad neuroprotectora y neuroplastica, que comprende la mutacion de al menos uno de los sitios de union al re...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: KRATJE, Ricardo, APARICIO, Gabriela I, ETCHEVERRIGARAY, Marina, SCORTICATI, Camila, BURGI-FISSOLO, Maria de los Milagros, DORELLA, Aquiles, OGGERO-EBERHARDT, Marcos
Format: Patent
Sprache:spa
Schlagworte:
Online-Zugang:Volltext bestellen
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue
container_start_page
container_title
container_volume
creator KRATJE, Ricardo
APARICIO, Gabriela I
ETCHEVERRIGARAY, Marina
SCORTICATI, Camila
BURGI-FISSOLO, Maria de los Milagros
DORELLA, Aquiles
OGGERO-EBERHARDT, Marcos
description Una eritropoyetina humana modificada con un tiempo de vida media en plasma aumentado, con actividad eritropoyetica menor al 0,5 % en relacion a una eritropoyetina nativa, que mantiene su capacidad neuroprotectora y neuroplastica, que comprende la mutacion de al menos uno de los sitios de union al receptor homodimerico o heterodimerico mediante la incorporacion de sitios consenso de N-glicosilacion A modified human erythropoietin with an increased plasma half-life, with an erythropoietic activity of less than 0.5% in relation to a native erythropoietin, which maintains the neuroprotective and neuroplastic capacity, which comprises the mutation of at least one of the binding sites the homodimeric or heterodimeric receptor by incorporating consensus sites for N-glycosylation.
format Patent
fullrecord <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_PE20210827A1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>PE20210827A1</sourcerecordid><originalsourceid>FETCH-epo_espacenet_PE20210827A13</originalsourceid><addsrcrecordid>eNrjZFBwDfIMCfIP8I90DfH0c1TwCPV1BFK-_i6ebp7Oji6OPAysaYk5xam8UJqbQdHNNcTZQze1ID8-tbggMTk1L7UkPsDVyMDI0MDCyNzR0JgYNQAE9yH2</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>ERITROPOYETINA HUMANA MODIFICADA</title><source>esp@cenet</source><creator>KRATJE, Ricardo ; APARICIO, Gabriela I ; ETCHEVERRIGARAY, Marina ; SCORTICATI, Camila ; BURGI-FISSOLO, Maria de los Milagros ; DORELLA, Aquiles ; OGGERO-EBERHARDT, Marcos</creator><creatorcontrib>KRATJE, Ricardo ; APARICIO, Gabriela I ; ETCHEVERRIGARAY, Marina ; SCORTICATI, Camila ; BURGI-FISSOLO, Maria de los Milagros ; DORELLA, Aquiles ; OGGERO-EBERHARDT, Marcos</creatorcontrib><description>Una eritropoyetina humana modificada con un tiempo de vida media en plasma aumentado, con actividad eritropoyetica menor al 0,5 % en relacion a una eritropoyetina nativa, que mantiene su capacidad neuroprotectora y neuroplastica, que comprende la mutacion de al menos uno de los sitios de union al receptor homodimerico o heterodimerico mediante la incorporacion de sitios consenso de N-glicosilacion A modified human erythropoietin with an increased plasma half-life, with an erythropoietic activity of less than 0.5% in relation to a native erythropoietin, which maintains the neuroprotective and neuroplastic capacity, which comprises the mutation of at least one of the binding sites the homodimeric or heterodimeric receptor by incorporating consensus sites for N-glycosylation.</description><language>spa</language><subject>HUMAN NECESSITIES ; HYGIENE ; MEDICAL OR VETERINARY SCIENCE ; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><creationdate>2021</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&amp;date=20210430&amp;DB=EPODOC&amp;CC=PE&amp;NR=20210827A1$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,780,885,25564,76547</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&amp;date=20210430&amp;DB=EPODOC&amp;CC=PE&amp;NR=20210827A1$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>KRATJE, Ricardo</creatorcontrib><creatorcontrib>APARICIO, Gabriela I</creatorcontrib><creatorcontrib>ETCHEVERRIGARAY, Marina</creatorcontrib><creatorcontrib>SCORTICATI, Camila</creatorcontrib><creatorcontrib>BURGI-FISSOLO, Maria de los Milagros</creatorcontrib><creatorcontrib>DORELLA, Aquiles</creatorcontrib><creatorcontrib>OGGERO-EBERHARDT, Marcos</creatorcontrib><title>ERITROPOYETINA HUMANA MODIFICADA</title><description>Una eritropoyetina humana modificada con un tiempo de vida media en plasma aumentado, con actividad eritropoyetica menor al 0,5 % en relacion a una eritropoyetina nativa, que mantiene su capacidad neuroprotectora y neuroplastica, que comprende la mutacion de al menos uno de los sitios de union al receptor homodimerico o heterodimerico mediante la incorporacion de sitios consenso de N-glicosilacion A modified human erythropoietin with an increased plasma half-life, with an erythropoietic activity of less than 0.5% in relation to a native erythropoietin, which maintains the neuroprotective and neuroplastic capacity, which comprises the mutation of at least one of the binding sites the homodimeric or heterodimeric receptor by incorporating consensus sites for N-glycosylation.</description><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2021</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNrjZFBwDfIMCfIP8I90DfH0c1TwCPV1BFK-_i6ebp7Oji6OPAysaYk5xam8UJqbQdHNNcTZQze1ID8-tbggMTk1L7UkPsDVyMDI0MDCyNzR0JgYNQAE9yH2</recordid><startdate>20210430</startdate><enddate>20210430</enddate><creator>KRATJE, Ricardo</creator><creator>APARICIO, Gabriela I</creator><creator>ETCHEVERRIGARAY, Marina</creator><creator>SCORTICATI, Camila</creator><creator>BURGI-FISSOLO, Maria de los Milagros</creator><creator>DORELLA, Aquiles</creator><creator>OGGERO-EBERHARDT, Marcos</creator><scope>EVB</scope></search><sort><creationdate>20210430</creationdate><title>ERITROPOYETINA HUMANA MODIFICADA</title><author>KRATJE, Ricardo ; APARICIO, Gabriela I ; ETCHEVERRIGARAY, Marina ; SCORTICATI, Camila ; BURGI-FISSOLO, Maria de los Milagros ; DORELLA, Aquiles ; OGGERO-EBERHARDT, Marcos</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_PE20210827A13</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>spa</language><creationdate>2021</creationdate><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</topic><toplevel>online_resources</toplevel><creatorcontrib>KRATJE, Ricardo</creatorcontrib><creatorcontrib>APARICIO, Gabriela I</creatorcontrib><creatorcontrib>ETCHEVERRIGARAY, Marina</creatorcontrib><creatorcontrib>SCORTICATI, Camila</creatorcontrib><creatorcontrib>BURGI-FISSOLO, Maria de los Milagros</creatorcontrib><creatorcontrib>DORELLA, Aquiles</creatorcontrib><creatorcontrib>OGGERO-EBERHARDT, Marcos</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>KRATJE, Ricardo</au><au>APARICIO, Gabriela I</au><au>ETCHEVERRIGARAY, Marina</au><au>SCORTICATI, Camila</au><au>BURGI-FISSOLO, Maria de los Milagros</au><au>DORELLA, Aquiles</au><au>OGGERO-EBERHARDT, Marcos</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>ERITROPOYETINA HUMANA MODIFICADA</title><date>2021-04-30</date><risdate>2021</risdate><abstract>Una eritropoyetina humana modificada con un tiempo de vida media en plasma aumentado, con actividad eritropoyetica menor al 0,5 % en relacion a una eritropoyetina nativa, que mantiene su capacidad neuroprotectora y neuroplastica, que comprende la mutacion de al menos uno de los sitios de union al receptor homodimerico o heterodimerico mediante la incorporacion de sitios consenso de N-glicosilacion A modified human erythropoietin with an increased plasma half-life, with an erythropoietic activity of less than 0.5% in relation to a native erythropoietin, which maintains the neuroprotective and neuroplastic capacity, which comprises the mutation of at least one of the binding sites the homodimeric or heterodimeric receptor by incorporating consensus sites for N-glycosylation.</abstract><oa>free_for_read</oa></addata></record>
fulltext fulltext_linktorsrc
identifier
ispartof
issn
language spa
recordid cdi_epo_espacenet_PE20210827A1
source esp@cenet
subjects HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
title ERITROPOYETINA HUMANA MODIFICADA
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-26T08%3A54%3A23IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=KRATJE,%20Ricardo&rft.date=2021-04-30&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3EPE20210827A1%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true